The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum
- PMID: 1650694
The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum
Abstract
Erythromycin is a macrolide antimicrobial chemically comprised of a 14-membered lactone ring substituted with a neutral (cladinose) and an amino (desosamine) sugar. Recently, a number of new macrolide molecules have been identified containing either 14-, 15- or 16-membered substituted lactone rings. In this study the authors have determined the in vitro activity of roxithromycin and clarithromycin (both 14-membered macrolides), azithromycin (a 15-membered macrolide or azalide) and midecamycin acetate (a 16-membered macrolide) against clinical isolates of Staphylococcus spp., (including methicillin-susceptible and -resistant isolates), Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Minimum inhibitory concentrations of the macrolides for the clinical isolates of Staphylococcus spp. examined were widely distributed. However, midecamycin acetate retained activity against those isolates of Staphylococcus spp. exhibiting inducible resistance to erythromycin and the other macrolides tested. Isolates characterised by constitutive resistance to erythromycin were also resistant to midecamycin acetate. All of the macrolides were very active against Legionella spp., with clarithromycin demonstrating the greatest potency (MIC range: less than or equal to 0.03-0.06 mg/l). Isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum were susceptible to all of the macrolides tested. However, erythromycin, roxithromycin, clarithromycin and azithromycin were poorly active against isolates of Mycoplasma hominis. By contrast, the same isolates were susceptible (MIC range: 0.008-0.12 mg/l) to midecamycin acetate.
Similar articles
-
In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.Scand J Infect Dis Suppl. 1988;53:12-7. Scand J Infect Dis Suppl. 1988. PMID: 2843982
-
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388. Eur J Clin Microbiol Infect Dis. 1990. PMID: 1964899
-
In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.Clin Microbiol Infect. 2001 Jul;7(7):362-6. doi: 10.1046/j.1198-743x.2001.00280.x. Clin Microbiol Infect. 2001. PMID: 11531981
-
The new macrolides: expanding the ways in antibiotic treatment.Bol Asoc Med P R. 1992 Jan;84(1):21-5. Bol Asoc Med P R. 1992. PMID: 1503585 Review.
-
[Azithromycin: critical points].Pathol Biol (Paris). 1995 Jun;43(6):488-97. Pathol Biol (Paris). 1995. PMID: 8539070 Review. French.
Cited by
-
Azithromycin (zithromax).Infect Dis Obstet Gynecol. 1996;4(4):215-20. doi: 10.1155/S1064744996000415. Infect Dis Obstet Gynecol. 1996. PMID: 18476095 Free PMC article.
-
Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.Drugs. 1994 Aug;48(2):297-326. doi: 10.2165/00003495-199448020-00011. Drugs. 1994. PMID: 7527329 Review.
-
Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study.Infection. 1999 May-Jun;27(3):198-202. doi: 10.1007/BF02561528. Infection. 1999. PMID: 10378132 Clinical Trial.
-
Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.Drugs. 1996 Mar;51(3):483-505. doi: 10.2165/00003495-199651030-00013. Drugs. 1996. PMID: 8882383 Review.
-
Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.Drugs. 1993 Oct;46(4):720-45. doi: 10.2165/00003495-199346040-00008. Drugs. 1993. PMID: 7506653 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous